Search results
Results from the WOW.Com Content Network
Multisystem inflammatory syndrome in children (MIS-C), or paediatric inflammatory multisystem syndrome (PIMS / PIMS-TS), or systemic inflammatory syndrome in COVID-19 (SISCoV), is a rare systemic illness involving persistent fever and extreme inflammation following exposure to SARS-CoV-2, the virus responsible for COVID-19. [7]
"Bouncing Back From COVID-19: Your Guide to Restoring Movement" (PDF). Johns Hopkins Medicine. Archived from the original (PDF) on 15 February 2021 "Guidelines on the Treatment and Management of Patients with COVID-19". Infectious Diseases Society of America (IDSA). "Coronavirus Disease 2019 (COVID-19) Treatment Guidelines".
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic . The symptoms of COVID‑19 can vary but often include fever, [ 7 ] fatigue, cough, breathing difficulties , loss of smell , and loss of taste .
The results of this study confirm the suspicions of child and youth care professionals that the COVID-19 lockdown has negative effects on the mental and social health of children and adolescents. In opinion papers, professionals elaborated on the vulnerability of this group and expected more feelings of loneliness, anxiety and depression, as ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Bebtelovimab was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in February 2022, [2] and revoked it in November 2022. [7] The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in people aged 12 years of age and older weighing at least 40 kilograms (88 lb) with a positive COVID-19 test, and who are at high risk for progression to ...
Bamlanivimab and etesevimab, administered together, are authorized in the United States for the treatment of mild-to-moderate COVID-19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 ...
Evidence is inconclusive regarding the efficacy of levosalbutamol versus salbutamol or salbutamol-levosalbutamol combinations, though levosalbutamol is believed to have a better safety profile due to its more selective binding to β 2 receptors (primarily in the lungs) versus β 1 (primarily in heart muscle). [2] [3]